Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 62

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Evolution of biofilm-forming pathogenic bacteria in the presence of nanoparticles and antibiotic: adaptation phenomena and cross-resistance

Mann, Riti, Holmes, Amy, McNeilly, Oliver, Cavaliere, Rosalia, Sotiriou, Georgios A., Rice, Scott A., Gunawan, Cindy·2021·Journal of Nanobiotechnology

Abstract

Background: Treatment of bacterial biofilms are difficult and in many cases, expensive. Bacterial biofilms are naturally more resilient to antimicrobial agents than their free-living planktonic counterparts, rendering the community growth harder to control. The present work described the risks of long-term use of an important alternative antimicrobial, silver nanoparticles (NAg), for the first time, on the dominant mode of bacterial growth. Results: NAg could inhibit the formation as well as eradicating an already grown biofilm of Pseudomonas aeruginosa, a pathogen notorious for its resilience to antibiotics. The biofilm-forming bacterium however, evolved a reduced sensitivity to the nanoparticle. Evidence suggests that survival is linked to the development of persister cells within the population. A similar adaptation was also seen upon prolonged exposures to ionic silver (Ag+). The persister population resumed normal growth after subsequent passage in the absence of silver, highlighting the potential risks of recurrent infections with long-term NAg (and Ag+) treatments of biofilm growth. The present study further observed a potential silver/antibiotic cross-resistance, whereby NAg (as well as Ag+) could not eradicate an already growing gentamicin-resistant P. aeruginosa biofilm. The phenomena is thought to result from the hindered biofilm penetration of the silver species. In contrast, both silver formulations inhibited biofilm formation of the resistant strain, presenting a promising avenue for the control of biofilm-forming antibiotic-resistant bacteria. Conclusion: The findings signify the importance to study the nanoparticle adaptation phenomena in the biofilm mode of bacterial growth, which are apparently unique to those already reported with the planktonic growth counterparts. This work sets the foundation for future studies in other globally significant bacterial pathogens when present as biofilms. Scientifically based strategies for management of pathogenic growth is necessary, particularly in this era of increasing antibiotic resistance. Graphic abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12951-021-01027-8

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 96

  1. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95–108. · DOI · Paper page
  2. Billings N, Ramirez Millan M, Caldara M, Rusconi R, Tarasova Y, Stocker R, et al. The extracellular matrix component Psl provides fast-acting antibiotic defense in Pseudomonas aeruginosa biofilms. PLoS Pathog. 2013;9:1–12. · DOI · Paper page
  3. Kumar A, Alam A, Rani M, Ehtesham NZ, Hasnain SE. Biofilms: Survival and defense strategy for pathogens. Int J Med Microbiol. 2017;307:481–9. · DOI · Paper page
  4. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280:295–8. · DOI · Paper page
  5. Zhao X, Yu Z, Ding T. Quorum-sensing regulation of antimicrobial resistance in bacteria. Microorganisms. 2020;8:425. · DOI · Paper page
  6. Hennequin C, Aumeran C, Robin F, Traore O, Forestier C. Antibiotic resistance and plasmid transfer capacity in biofilm formed with a CTX-M-15-producing Klebsiella pneumoniae isolate. J Antimicrob Chemother. 2012;67:2123–30. https://doi.org/10.1093/jac/dks169. · DOI
  7. Makabenta JMV, Nabawy A, Li CH, Schmidt-Malan S, Patel R, Rotello VM. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat Rev Microbiol. 2021;19:23–36. https://doi.org/10.1038/s41579-020-0420-1. · DOI · Paper page
  8. Wong KKY, Liu X. Silver nanoparticles—the real “silver bullet” in clinical medicine? Medchemcomm. 2010;1:125–31. · DOI · Paper page
  9. Panácek A, Smékalová M, Kilianová M, Prucek R, Bogdanová K, Věcěrová R, et al. Strong and nonspecific synergistic antibacterial efficiency of antibiotics combined with silver nanoparticles at very low concentrations showing no cytotoxic effect. Molecules. 2016;21:1–17.
  10. Qayyum S, Oves M, Khan AU. Obliteration of bacterial growth and biofilm through ROS generation by facilely synthesized green silver nanoparticles. PLoS ONE. 2017;12:1–18. · DOI · Paper page
  11. Siddique MH, Aslam B, Imran M, Ashraf A, Nadeem H, Hayat S, et al. Effect of silver nanoparticles on biofilm formation and EPS production of multidrug-resistant Klebsiella pneumoniae. Biomed Res Int. 2020. https://doi.org/10.1155/2020/6398165. · DOI · Paper page
  12. Gunawan C, Teoh WY, Marquis CP, Lifia J, Amal R. Reversible antimicrobial photoswitching in nanosilver. Small. 2009;5:341–4. · DOI · Paper page
  13. Sotiriou GA, Pratsinis SE. Antibacterial activity of nanosilver ions and particles. Environ Sci Technol. 2010;44:5649–54. · DOI · Paper page
  14. Faiz MB, Amal R, Marquis CP, Harry EJ, Sotiriou GA, Rice SA, et al. Nanosilver and the microbiological activity of the particulate solids versus the leached soluble silver. Nanotoxicology. 2018;12:263–73. https://doi.org/10.1080/17435390.2018.1434910. · DOI
  15. Sotiriou GA, Meyer A, Knijnenburg JTN, Panke S, Pratsinis SE. Quantifying the origin of released Ag+ ions from nanosilver. Langmuir. 2012;28:15929–36. · DOI · Paper page
  16. Gunawan C, Faiz MB, Mann R, Ting SRS, Sotiriou GA, Marquis CP, et al. Nanosilver targets the bacterial cell envelope: the link with generation of reactive oxygen radicals. ACS Appl Mater Interfaces. 2020;12:5557–68. · DOI
  17. Lemire JA, Harrison JJ, Turner RJ. Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat Rev Microbiol. 2013;11:371–84. · DOI · Paper page
  18. Liu J, Sonshine DA, Shervani S, Hurt RH. Controlled release of biologically active silver from nanosilver surfaces. ACS Nano. 2010;4:6903–13. https://doi.org/10.1021/nn102272n. · DOI · Paper page
  19. Panáček A, Smékalová M, Večeřová R, Bogdanová K, Röderová M, Kolář M, et al. Silver nanoparticles strongly enhance and restore bactericidal activity of inactive antibiotics against multiresistant Enterobacteriaceae. Colloids Surfaces B Biointerfaces. 2016;142:392–9. · DOI · Paper page
  20. Lara HH, Ayala-Núñez NV, del Turrent LCI, Padilla CR. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World J Microbiol Biotechnol. 2010;26:615–21. · DOI · Paper page
  21. Valentin E, Bottomley AL, Chilambi GS, Harry EJ, Amal R, Sotiriou GA, et al. Heritable nanosilver resistance in priority pathogen: a unique genetic adaptation and comparison with ionic silver and antibiotics. Nanoscale. 2020;12:2384–92. · DOI
  22. Gunawan C, Teoh WY, Marquis CP, Amal R. Induced adaptation of Bacillus sp. to antimicrobial nanosilver. Small. 2013;9:3554–60. · DOI
  23. Panáček A, Kvítek L, Smékalová M, Večeřová R, Kolář M, Röderová M, et al. Bacterial resistance to silver nanoparticles and how to overcome it. Nat Nanotechnol. 2018;13:65–71. https://doi.org/10.1038/s41565-017-0013-y. · DOI · Paper page
  24. Ellis DH, Maurer-Gardner EI, Sulentic CEW, Hussain SM. Silver nanoparticle antibacterial efficacy and resistance development in key bacterial species. Biomed Phys Eng Express. 2019;5:015013. · DOI
  25. Graves JL, Tajkarimi M, Cunningham Q, Campbell A, Nonga H, Harrison SH, et al. Rapid evolution of silver nanoparticle resistance in Escherichia coli. Front Genet. 2015. https://doi.org/10.3389/fgene.2015.00042. · DOI · Paper page
  26. Mijnendonckx K, Leys N, Mahillon J, Silver S, Van Houdt R. Antimicrobial silver: uses, toxicity and potential for resistance. Biometals. 2013;26:609–21. · DOI · Paper page
  27. Singh N, Paknikar KM, Rajwade J. RNA-sequencing reveals a multitude of effects of silver nanoparticles on Pseudomonas aeruginosa biofilms. Environ Sci Nano. 2019;6:1812–28. · DOI
  28. Zhang Y, Pan X, Liao S, Jiang C, Wang L, Tang Y, et al. Quantitative proteomics reveals the mechanism of silver nanoparticles against multidrug-resistant Pseudomonas aeruginosa biofilms. J Proteome Res. 2020;19:3109–22. · DOI
  29. Estevez MB, Raffaelli S, Mitchell SG, Faccio R, Alborés S. Biofilm eradication using biogenic silver nanoparticles. Molecules. 2020;25:1–14. · DOI
  30. Gholamrezazadeh M, Shakibaie MR, Monirzadeh F, Masoumi S, Hashemizadeh Z. Effect of nano-silver, nano-copper, deconex and benzalkonium chloride on biofilm formation and expression of transcription regulatory quorum sensing gene (rh1R) in drug-resistance Pseudomonas aeruginosa burn isolates. Burns. 2018;44:700–8. https://doi.org/10.1016/j.burns.2017.10.021. · DOI
  31. Habash MB, Park AJ, Vis EC, Harris RJ, Khursigara CM. Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 Biofilms. Antimicrob Agents Chemother. 2014;58:5818–30. · DOI
  32. Kalishwaralal K, BarathManiKanth S, Pandian SRK, Deepak V, Gurunathan S. Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and Staphylococcus epidermidis. Colloids Surfaces B Biointerfaces. 2010;79:340–4. https://doi.org/10.1016/j.colsurfb.2010.04.014. · DOI · Paper page
  33. Loo CY, Young PM, Cavaliere R, Whitchurch CB, Lee WH, Rohanizadeh R. Silver nanoparticles enhance Pseudomonas aeruginosa PAO1 biofilm detachment. Drug Dev Ind Pharm. 2014;40:719–29. · DOI
  34. Markowska K, Grudniak AM, Wolska KI. Silver nanoparticles as an alternative strategy against bacterial biofilms. Acta Biochim Pol. 2013;60:523–30.
  35. Mohanta YK, Biswas K, Jena SK, Hashem A, Abd-Allah EF, Mohanta TK. Anti-biofilm and antibacterial activities of silver nanoparticles synthesized by the reducing activity of phytoconstituents present in the indian medicinal plants. Front Microbiol. 2020;11:1–15. · DOI · Paper page
  36. Radzig MA, Nadtochenko VA, Koksharova OA, Kiwi J, Lipasova VA, Khmel IA. Antibacterial effects of silver nanoparticles on gram-negative bacteria: Influence on the growth and biofilms formation, mechanisms of action. Colloids Surfaces B Biointerfaces. 2013;102:300–6. https://doi.org/10.1016/j.colsurfb.2012.07.039. · DOI · Paper page
  37. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37:177–92. https://doi.org/10.1016/j.biotechadv.2018.11.013. · DOI · Paper page
  38. Römling U, Kjelleberg S, Normark S, Nyman L, Uhlin BE, Åkerlund B. Microbial biofilm formation: a need to act. J Intern Med. 2014;276:98–110. https://doi.org/10.1111/joim.12242. · DOI · Paper page
  39. Ramírez-Estrada S, Borgatta B, Rello J. Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist. 2016;9:7–18.
  40. Long Y, Fu W, Li S, Ren H, Li M, Liu C, et al. Identification of novel genes that promote persister formation by repressing transcription and cell division in Pseudomonas aeruginosa. J Antimicrob Chemother. 2019;74:2575–87. · DOI
  41. Chew SC, Yam JKH, Matysik A, Seng ZJ, Klebensberger J, Givskov M, et al. Matrix polysaccharides and SiaD diguanylate cyclase alter community structure and competitiveness of Pseudomonas aeruginosa during dual-species biofilm development with Staphylococcus aureus. MBio. 2018;9:1–16. · DOI
  42. Billings N, Ramirez Millan M, Caldara M, Rusconi R, Tarasova Y, Stocker R, et al. The extracellular matrix component Psl provides fast-acting antibiotic defense in Pseudomonas aeruginosa biofilms. Parsek MR, editor. PLoS Pathog. 2013;9:e1003526. https://doi.org/10.1371/journal.ppat.1003526. · DOI · Paper page
  43. Franklin MJ, Nivens DE, Weadge JT, LynneHowell P. Biosynthesis of the Pseudomonas aeruginosa extracellular polysaccharides, alginate, Pel, and Psl. Front Microbiol. 2011. https://doi.org/10.3389/fmicb.2011.00167. · DOI · Paper page
  44. Park SY, Park HJ, Moon SM, Park KH, Chong YP, Kim MN, et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis. 2012;12:1–6. · DOI
  45. Joo EJ, Kang CI, Ha YE, Park SY, Kang SJ, Wi YM, et al. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection. 2011;39:309–18. https://doi.org/10.1007/s15010-011-0124-6. · doi:10.1007/s15010-011-0124-6
  46. Kędziora A, Speruda M, Krzyżewska E, Rybka J, Łukowiak A, Bugla-Płoskońska G. Similarities and differences between silver ions and silver in nanoforms as antibacterial agents. Int J Mol Sci. 2018;19:1–17. · DOI · Paper page
  47. Markowska K, Grudniak AM, Krawczyk K, Wróbel I, Wolska KI. Modulation of antibiotic resistance and induction of a stress response in Pseudomonas aeruginosa by silver nanoparticles. J Med Microbiol. 2014;63:849–54. · DOI
  48. Singh P, Pandit S, Beshay M, Mokkapati VRSS, Garnaes J, Olsson ME, et al. Anti-biofilm effects of gold and silver nanoparticles synthesized by the Rhodiola rosea rhizome extracts. Artif Cells Nanomed Biotechnol. 2018;46:S886–99. https://doi.org/10.1080/21691401.2018.1518909. · DOI
  49. Gurunathan S, Han JW, Kwon D-N, Kim J-H. Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria. Nanoscale Res Lett. 2014;9:1–17. · DOI · Paper page
  50. Madhi M, Hasani A, Mojarrad JS, Rezaee MA, Zarrini G, Davaran S. Nano-strategies in pursuit of efflux pump activeness in Acinetobacter baumannii and Pseudomonas aeruginosa. Gene Rep. 2020. https://doi.org/10.1016/j.genrep.2020.100915. · doi:10.1016/j.genrep.2020.100915
  51. Martínez-Castañón GA, Niño-Martínez N, Martínez-Gutierrez F, Martínez-Mendoza JR, Ruiz F. Synthesis and antibacterial activity of silver nanoparticles with different sizes. J Nanoparticle Res. 2008;10:1343–8. https://doi.org/10.1007/s11051-008-9428-6. · DOI · Paper page
  52. Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli. Appl Environ Microbiol. 2007;73:1712–20. · DOI · Paper page
  53. Ayala-Núñez NV, Lara Villegas HH, Del CarmenIxtepanTurrent L, PadillaRodríguez C. Silver nanoparticles toxicity and bactericidal effect against methicillin-resistant Staphylococcus aureus: nanoscale does matter. NanoBiotechnology. 2009;5:2–9. https://doi.org/10.1007/s12030-009-9029-1. · DOI · Paper page
  54. Mulley G, Jenkins ATA, Waterfield NR. Inactivation of the antibacterial and cytotoxic properties of silver ions by biologically relevant compounds. PLoS ONE. 2014;9:2–10. · DOI
  55. Radtsig M, Koksharova OA, Khmel IA. Antibacterial effects of silver ions: effect on gram-negative bacteria growth and biofilm formation. Mol Gen Mikrobiol Virusol. 2009;4:27–31.
  56. Tseng KH, Lee HL, Tien DC, Tang YL, Kao YS. A study of antibioactivity of nanosilver colloid and silver ion solution. Adv Mater Sci Eng. 2014;371483:1–6. · doi:10.1155/2014/371483
  57. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009;27:76–83. · DOI · Paper page
  58. Gordon O, Slenters TV, Brunetto PS, Villaruz AE, Sturdevant DE, Otto M, et al. Silver coordination polymers for prevention of implant infection: thiol interaction, impact on respiratory chain enzymes, and hydroxyl radical induction. Antimicrob Agents Chemother. 2010;54:4208–18. · DOI · Paper page
  59. Park HJ, Kim JY, Kim J, Lee JH, Hahn JS, Gu MB, et al. Silver-ion-mediated reactive oxygen species generation affecting bactericidal activity. Water Res. 2009;43:1027–32. · DOI · Paper page
  60. Bahari S, Zeighami H, Mirshahabi H, Roudashti S, Haghi F. Inhibition of Pseudomonas aeruginosa quorum sensing by subinhibitory concentrations of curcumin with gentamicin and azithromycin. J Glob Antimicrob Resist. 2017;10:21–8. · DOI
  61. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for Isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004;42:1915–22. · DOI · Paper page
  62. Das MC, Sandhu P, Gupta P, Rudrapaul P, De UC, Tribedi P, et al. Attenuation of Pseudomonas aeruginosa biofilm formation by Vitexin: a combinatorial study with azithromycin and gentamicin. Sci Rep. 2016;6:1–13. · DOI · Paper page
  63. Al-Qaysi AMK, Al-Ouqaili MTS, Al-Meani SAL. Ciprofloxacin-and gentamicin-mediated inhibition of Pseudomonas aeruginosa biofilms is enhanced when combined the volatile oil from Eucalyptus camaldulensis. Syst Rev Pharm. 2020;11:98–105.
  64. Pye C. Pseudomonas aeruginosa bacterial biofilms. Ontario: The University of Guelph; 2013.
  65. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb Perspect Med. 2016;6:1–18. · DOI · Paper page
  66. Martin NL, Beveridge TJ. Gentamicin interaction with Pseudomonas aeruginosa cell envelope. Antimicrob Agents Chemother. 1986;29:1079–87. · DOI
  67. Kadurugamuwa JL, Clarke AJ, Beveridge TJ. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol. 1993;175:5798–805. · DOI
  68. Palanisamy NK, Ferina N, Amirulhusni AN, Mohd-Zain Z, Hussaini J, Ping LJ, et al. Antibiofilm properties of chemically synthesized silver nanoparticles found against Pseudomonas aeruginosa. J Nanobiotechnology. 2014. https://doi.org/10.1186/1477-3155-12-2. · DOI · Paper page
  69. Martinez-Gutierrez F, Boegli L, Agostinho A, Sánchez EM, Bach H, Ruiz F, et al. Anti-biofilm activity of silver nanoparticles against different microorganisms. Biofouling. 2013;29:651–60. · DOI · Paper page
  70. Lemire JA, Kalan L, Bradu A, Turner RJ. Silver oxynitrate, an unexplored silver compound with antimicrobial and antibiofilm activity. Antimicrob Agents Chemother. 2015;59:4031–9. · DOI
  71. Macià MD, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect. 2014;20:981–90. · DOI · Paper page
  72. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 2001;45:999–1007. · DOI · Paper page
  73. Park HJ, Park S, Roh J, Kim S, Choi K, Yi J, et al. Biofilm-inactivating activity of silver nanoparticles: a comparison with silver ions. J Ind Eng Chem. 2013;19:614–9. https://doi.org/10.1016/j.jiec.2012.09.013. · doi:10.1016/j.jiec.2012.09.013
  74. Agarwal G, Kapil A, Kabra SK, Das BK, Dwivedi SN. In vitro efficacy of ciprofloxacin and gentamicin against a biofilm of Pseudomonas aeruginosa and its free-living forms. Natl Med J India. 2005;18:184–6.
  75. Muller M, Merrett ND. Pyocyanin production by Pseudomonas aeruginosa confers resistance to ionic silver. Antimicrob Agents Chemother. 2014;58:5492–9. · DOI
  76. Abbas HA, Serry FM, El-masry EM. Combating Pseudomonas aeruginosa biofilms by potential biofilm inhibitors. Asian J Res Pharm Sci. 2012;2:66–72.
  77. Bryan LE, Shahrabadi MS, Van Den Elzen HM. Gentamicin resistance in Pseudomonas aeruginosa: R-factor-mediated resistance. Antimicrob Agents Chemother. 1974;6:191–9. · doi:10.1128/aac.6.2.191
  78. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:479–87. · DOI · Paper page
  79. Bryan LE, Haraphongse R, Van Den Elzen HM. Gentamicin resistance in clinical-isolates of Pseudomonas aeruginosa associated with diminished gentamicin accumulation and no detectable enzymatic modification. J Antibiot. 1976;29:743–53. · doi:10.7164/antibiotics.29.743
  80. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999;43:415–7. · DOI · Paper page
  81. Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14:320–30. https://doi.org/10.1038/nrmicro.2016.34. · DOI · Paper page
  82. Dewachter L, Fauvart M, Michiels J. Bacterial heterogeneity and antibiotic survival: understanding and combatting persistence and heteroresistance. Mol Cell. 2019;76:255–67. · DOI · Paper page
  83. Grassi L, Di Luca M, Maisetta G, Rinaldi AC, Esin S, Trampuz A, et al. Generation of persister cells of Pseudomonas aeruginosa and Staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents. Front Microbiol. 2017. https://doi.org/10.3389/fmicb.2017.01917/full. · doi:10.3389/fmicb.2017.01917/full
  84. Malone JG. Role of small colony variants in persistence of Pseudomonas aeruginosa infections in cystic fibrosis lungs. Infect Drug Resist. 2015;8:237–47. · DOI
  85. Evans TJ. Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis. Future Microbiol. 2015;10:231–9. · DOI
  86. Salas-Orozco M, Niño-Martínez N, Martínez-Castañón GA, Méndez FT, Jasso MEC, Ruiz F. Mechanisms of resistance to silver nanoparticles in endodontic bacteria: a literature review. J Nanomater. 2019. https://doi.org/10.1155/2019/7630316. · DOI
  87. Ayrapetyan M, Williams TC, Oliver JD. Bridging the gap between viable but non-culturable and antibiotic persistent bacteria. Trends Microbiol Elsevier Ltd. 2015;23:7–13. · DOI · Paper page
  88. Grant SS, Hung DT. Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. Virulence. 2013;4:273–83. · DOI · Paper page
  89. Wu Y, Vulić M, Keren I, Lewis K. Role of oxidative stress in persister tolerance. Antimicrob Agents Chemother. 2012;56:4922–6. · DOI · Paper page
  90. Jenal U, Reinders A, Lori C. Cyclic di-GMP: second messenger extraordinaire. Nat Rev Microbiol. 2017;15:271–84. · DOI · Paper page
  91. Liou GF, Yoshizawa S, Courvalin P, Galimand M. Aminoglycoside resistance by ArmA-mediated ribosomal 16 S methylation in human bacterial pathogens. J Mol Biol. 2006;359:358–64. · DOI
  92. Ma L, Jackson KD, Landry RM, Parsek MR, Wozniak DJ. Analysis of Pseudomonas aeruginosa conditional Psl variants reveals roles for the psl polysaccharide in adhesion and maintaining biofilm structure postattachment. J Bacteriol. 2006;188:8213–21. · DOI · Paper page
  93. Klockgether J, Munder A, Neugebauer J, Davenport CF, Stanke F, Larbig KD, et al. Genome diversity of Pseudomonas aeruginosa PAO1 laboratory strains. J Bacteriol. 2010;192:1113–21. · DOI · Paper page
  94. Eng RHK, Padberg FT, Smith SM, Tan EN, Cherubin CE. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother. 1991;35:1824–8. · DOI · Paper page
  95. Holmes AM, Lim J, Studier H, Roberts MS. Varying the morphology of silver nanoparticles results in differential toxicity against micro-organisms, HaCaT keratinocytes and affects skin deposition. Nanotoxicology. 2016;10:1503–14. · DOI
  96. Podlipensky A, Lange J, Seifert G, Graener H, Cravetchi I. Second-harmonic generation from ellipsoidal silver nanoparticles embedded in silica glass. Opt Lett. 2003;28:718. · doi:10.1364/ol.28.000716

Cited by

See all 62

Metadata

Authors
Mann, R., Holmes, A., McNeilly, O., Cavaliere, R., Sotiriou, G. A., Rice, S. A., & Gunawan, C.
Venue
Journal of Nanobiotechnology
Published
2021-09-27
Volume
19
Issue
1
ISSN
1477-3155
Cited by
62
References
7
Language
en
Licence
Funders
Australian Research Council Discovery Project (ARC DP180100474)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of biofilm-forming pathogenic bacteria in the presence of nanoparticles and antibiotic: adaptation phenomena and cross-resistance. https://app.cochat.ai/papers/10.1186/s12951-021-01027-8
The paper
Mann, R., Holmes, A., McNeilly, O., Cavaliere, R., Sotiriou, G. A., Rice, S. A., & Gunawan, C. (2021). Evolution of biofilm-forming pathogenic bacteria in the presence of nanoparticles and antibiotic: adaptation phenomena and cross-resistance. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-021-01027-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.